Scott Gottlieb Departs FDA – Bank Analysts React

Scott Gottlieb Departs FDA – Bank Analysts React
The U.S. Food and Drug Administration [Public domain], <a href="">via Wikimedia Commons</a>

Analysts comment on the announcement of FDA Commissioner Scott Gottlieb’s resignation on 03/06/2019, which was unexpected by many in and outside the industry.

Get The Full Series in PDF

Get the entire 10-part series on Charlie Munger in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q4 hedge fund letters, conference, scoops etc

Analysts' comments on Scott Gottlieb's resignation

Piper Jaffray

Li Lu On Understanding Competitive Advantage In 2021

Bruce GreenwaldOn April 9th 2021, Bruce Greenwald, the founding director of the Heilbrunn Center for Graham and Dodd Investing at Columbia Business School, sat down for a Fireside Chat with Li Lu, the founder and chairman of Himalaya Capital as part of the 13th Columbia China Business Conference. Q1 2021 hedge fund letters, conferences and more Read More

Remain largely bullish on biopharma, but also acknowledge a new and unexpected source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, we think Dr. Gottlieb was about as market friendly, patient focused and industry friendly as one could have hoped. By contrast, it’s easy to forget that before Dr. Scott Gottlieb was named FDA commissioner, a leading candidate advocated for gutting approval standards as well as FDA itself, which we think would have been decidedly negative for the industry.

Raymond James

Scott Gottlieb's resignation stunned Washington health circles today - including those within HHS.


  • This should have no impact on any pending FDA PDUFA dates. Drug approvals will continue to move forward.
  • The focus on tobacco and e-cigarettes is likely to take a back seat as that was a personal priority for him.
  • Scott Gottlieb was a friend of the industry largely speaking, and Republicans usually put in place FDA Commissioners that drug companies like.
  • This could open the door to things like importation as Gottlieb was a strong advocate against any potential action on that.
  • Other initiatives Gottlieb has undertaken will continue because his staff is still running the agency, but progress will likely slow.

The unexpected nature of this should not lead to overreaction. FDA has operated without a permanent commissioner before and can do so again.

Wells Fargo

FDA Commissioner Scott Gottlieb has resigned. There are not many details about his resignation, other than the HHS Secretary praising his work while at the FDA and press accounts that Gottlieb had been commuting from Washington DC to his home in Connecticut and is leaving the FDA to spend more time with his family. His short tenure has been marked by great progress in drug approvals and changes to support lowering the cost of medications.

Previous article Crypto Winter Is Leaving As Blockchain Bounces Back?
Next article Galaxy Watch Active Pre-Order And More: Amazon’s Easter Deals
Jacob Wolinsky is the founder of, a popular value investing and hedge fund focused investment website. Jacob worked as an equity analyst first at a micro-cap focused private equity firm, followed by a stint at a smid cap focused research shop. Jacob lives with his wife and four kids in Passaic NJ. - Email: jacob(at) - Twitter username: JacobWolinsky - Full Disclosure: I do not purchase any equities anymore to avoid even the appearance of a conflict of interest and because at times I may receive grey areas of insider information. I have a few existing holdings from years ago, but I have sold off most of the equities and now only purchase mutual funds and some ETFs. I also own a few grams of Gold and Silver

No posts to display